|
|
???tair.name??? >
???browser.page.title.author???
|
"bai ly"???jsp.browse.items-by-author.description???
Showing items 36-45 of 52 (6 Page(s) Totally)
<< < 1 2 3 4 5 6 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2021-05 |
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Bai, LY;Li, CP;Chen, JS;Yang, SH;Kuo, YC;Chao, Y;Hsieh, YY;Kao, HF;Hsiao, CF;Chen, LT |
| 國家衛生研究院 |
2021-03-20 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Nishiyama, T;Chen, LT;Kang, YK |
| 中山醫學大學 |
2021 |
Analysis of TRIM21 Genetic Variants on the Clinicopathologic Characteristics of Patients with Hepatocellular Carcinoma
|
Lee, HL; Chien, YC; Chiang, WL; Wang, HL; Hsueh, KC; Chen, CH; Chen, SC; Wu, TK; Pan, YR; Bai, LY; Yang, SF; Yu, YL |
| 中山醫學大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study
|
Chiu, TJ; Su, YY; Yang, SH; Li, CP; Bai, LY; Chiang, NJ; Chuang, SC; Shan, YS; Chan, DC; Chen, LT; Yen, CJ; Peng, CM; Chen, YY; Chen, JS; Chou, WC |
| 中山醫學大學 |
2021 |
TRIM21 Polymorphisms are associated with Susceptibility and Clinical Status of Oral Squamous Cell Carcinoma patients
|
Chuang, CY; Chien, YC; Lin, CW; Chou, CH; Chen, SC; Liu, CL; Bai, LY; Yang, SF; Yu, YL |
| 國家衛生研究院 |
2020-12-29 |
Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan
|
Chen, CY;Liang, SH;Su, YY;Chiang, NJ;Wang, HC;Chiu, CF;Chen, LT;Bai, LY |
| 國家衛生研究院 |
2020-09 |
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
|
Boku, N;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2020-02 |
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study
|
Valle, JW;Bai, LY;Orlova, R;Van Cutsem, E;Alfonso, JA;Chen, LT;Obermannova, R;Ettrich, TJ;Chen, JS;Wasan, HS;Denlinger, CS;Vogel, A;He, AR;Bousmans, N;Girvan, AC;Zhang, W;Walgren, RA;Carlesi, R;Oh, DY |
| 國家衛生研究院 |
2019-12-20 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, LT;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Kang, YK;Boku, N |
| 國家衛生研究院 |
2019-10 |
A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FO
|
Chen, LT;Hitre, E;Lee, WJ;Bai, LY;Papai, Z;Kang, SY;Dvorkin, M;Choi, HJ;Oh, SC;Artru, P;Bachet, JB |
Showing items 36-45 of 52 (6 Page(s) Totally)
<< < 1 2 3 4 5 6 > >>
View [10|25|50] records per page
|
